Viridian Therapeutics announced positive topline data from their THRIVE Phase 3 clinical trial for VRDN-001 (veligrotug), a potential treatment for active thyroid eye disease (TED). The trial met all primary and secondary endpoints, demonstrating veligrotug’s effectiveness in reducing symptoms and improving patient outcomes.